It’s amazing how much can happen in a year. We announced a $112 million Series B funding round and a strategic partnership with Roche. We expanded our executive suite, welcomed two new board members, and we were named a “Fierce 15” company of the year. And today, we are unveiling a new website that reflects how far we have come and the future we are working toward.
It took a great deal of work and lots of conversation to reach this point. We are excited to communicate the full breadth of our offerings because there is nothing else like it in the industry. At ShapeTX, we recognize that the key to unlocking effective gene therapies lies at the intersection of innovating each component of a programmable medicine – the RNA (the medicine itself), the viral vectors (how the medicine is delivered into your body), and the manufacturing (our ability to make sufficient medicines to treat everyone who needs it).
The momentum from this past year is propelling us toward realizing our core mission of making safe, effective, and accessible treatments for Alzheimer’s, Parkinson’s and a host of other genetic diseases. Imagine a future where the untapped and unlimited potential of artificial intelligence and RNA biology can be leveraged to develop cures for intractable genetic diseases. It’s ambitious, but achievable. At the heart of our company are individuals from diverse backgrounds and varying expertise, all united by a shared commitment to this goal.
We welcome you to explore our website and learn more about our mission at ShapeTX.
